Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients? - Wikidata - wikimedia - TriplyDB

Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?

Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?

http://www.wikidata.org/entity/Q37534534

about

Intensive therapies for mantle cell lymphoma: time for a disease-specific approach?Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.

P2860

Q24299054-308BB52D-7117-46B4-990E-B456BB6E3010 Q33394663-292E4D3B-9A10-4083-9302-69DCB25E1ABC Q33399582-1588CC5B-A681-4FA7-BEAA-A39DB7A1F167

P2860

Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?

http://www.wikidata.org/entity/Q37534534

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Mantle cell lymphoma - does pr ...... survival for younger patients?

@en

Mantle cell lymphoma - does pr ...... survival for younger patients?

@nl

type

label

Mantle cell lymphoma - does pr ...... survival for younger patients?

@en

Mantle cell lymphoma - does pr ...... survival for younger patients?

@nl

prefLabel

Mantle cell lymphoma - does pr ...... survival for younger patients?

@en

Mantle cell lymphoma - does pr ...... survival for younger patients?

@nl

P1433

Q37534534-9917C10E-987A-4DAE-B655-9C2880493F1A

P1476

Q37534534-E0D2C6E3-B345-4A0F-BA59-28DC29BA212A

P2093

Q37534534-1749AB84-18C3-406C-89E4-70C30BFB43B5

Q37534534-4873E675-8D2A-42E8-94D7-0A134536A3AD

Q37534534-4EF6DFE1-C201-40FB-A7DB-7FB5AE48BC61

Q37534534-80981EA3-A54D-48F7-8229-2200AC03F852

Q37534534-8EC7C3D5-F043-4B1C-AAC5-2CC046735B93

Q37534534-CA6C4094-4B9C-462C-840F-9705BBCBC531

P2860

Q37534534-0F09CAB1-6A34-452D-8E3A-5080102271E5

Q37534534-18360ED4-43C0-4DEF-8562-A2E1B202D051

Q37534534-192EADDA-E5B8-4FFF-900C-02F60D94086A

Q37534534-1E06AAB8-30CB-465F-86FA-81A105C4E042

Q37534534-219A16A6-F31B-4074-B96A-A337D749F7BA

Q37534534-28FFE2F5-4245-4C32-95A2-FEAD23DB6460

Q37534534-2AA858AB-8921-44A2-BFBF-9DCEBF42E7CC

Q37534534-2D3EB3EB-E4A1-46DD-B8AC-26D9D64E08AA

Q37534534-2ED84357-1685-4EC9-822F-AE88A5949F23

Q37534534-3071B0B8-B96D-436B-97D3-CF7149B2EBF7

P304

Q37534534-C1047C05-3610-4E5D-B8CC-CCECA3A54017

P31

Q37534534-8EBF0BE0-D29B-4376-82ED-A6CC59E055DF

P356

Q37534534-4796B951-B629-4669-93CB-9360C44AB7B5

P433

Q37534534-88B641E9-7D12-40E5-A1A7-F85A3B4F0772

P478

Q37534534-1B9D2579-499F-4960-8BAB-6C2DE64B685A

P50

Q37534534-5A9229A4-7BCF-4889-811E-DE0109188B8E

Q37534534-9D63B0E2-6A6A-43AD-8A42-6645FF86F69A

P577

Q37534534-F5F74A25-AFA8-4FDB-92FC-3D0CE7303D60

P698

Q37534534-5380B9F7-B93E-40AE-BC09-516BBFAEEA6C

P356

10428190903040030

P1433

Leukemia & Lymphoma

P1476

Mantle cell lymphoma - does pr ...... survival for younger patients?

@en

P2093

Anna Laurell

http://www.w3.org/2001/XMLSchema#string

Arne Kolstad

http://www.w3.org/2001/XMLSchema#string

Christian Geisler

http://www.w3.org/2001/XMLSchema#string

Mantle Cell Lymphoma Subcommittee

http://www.w3.org/2001/XMLSchema#string

Nordic Lymphoma Group

http://www.w3.org/2001/XMLSchema#string

Riikka Räty

http://www.w3.org/2001/XMLSchema#string

P2860

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group.

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma.

Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.

Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries.

P304

1249-1256

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428190903040030

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P50

Christian Geisler

P577

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19562619

http://www.w3.org/2001/XMLSchema#string